A detailed history of Bank Of America Corp transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 169,105 shares of CABA stock, worth $695,021. This represents 0.0% of its overall portfolio holdings.

Number of Shares
169,105
Previous 238,103 28.98%
Holding current value
$695,021
Previous $4.06 Million 68.88%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$7.22 - $18.82 $498,165 - $1.3 Million
-68,998 Reduced 28.98%
169,105 $1.26 Million
Q1 2024

May 15, 2024

BUY
$16.79 - $25.38 $1.3 Million - $1.97 Million
77,583 Added 48.33%
238,103 $4.06 Million
Q4 2023

Feb 14, 2024

BUY
$12.21 - $23.36 $1.65 Million - $3.15 Million
135,022 Added 529.54%
160,520 $3.64 Million
Q2 2023

Aug 14, 2023

BUY
$7.65 - $13.95 $127,349 - $232,225
16,647 Added 188.08%
25,498 $329,000
Q1 2023

May 12, 2023

BUY
$7.08 - $12.62 $53,992 - $96,240
7,626 Added 622.53%
8,851 $73,000
Q4 2022

Feb 10, 2023

SELL
$0.64 - $9.3 $5,100 - $74,111
-7,969 Reduced 86.68%
1,225 $11,000
Q3 2022

Nov 14, 2022

SELL
$0.63 - $2.05 $3,813 - $12,408
-6,053 Reduced 39.7%
9,194 $6,000
Q2 2022

Aug 12, 2022

SELL
$0.99 - $2.11 $16,960 - $36,148
-17,132 Reduced 52.91%
15,247 $16,000
Q1 2022

May 16, 2022

BUY
$1.68 - $3.92 $42,450 - $99,050
25,268 Added 355.34%
32,379 $66,000
Q4 2021

Feb 08, 2022

SELL
$3.36 - $14.64 $24,850 - $108,277
-7,396 Reduced 50.98%
7,111 $27,000
Q3 2021

Nov 15, 2021

SELL
$7.0 - $12.5 $39,886 - $71,225
-5,698 Reduced 28.2%
14,507 $176,000
Q2 2021

Sep 13, 2021

BUY
$7.2 - $11.73 $145,476 - $237,004
20,205 New
20,205 $174,000

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $119M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.